3 results
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Primary end points:Safety (>1 toxic death per arm) and tolerability (relevant grade 4 toxicities) in not more than 33% of patients for the three treatment arms.Secondary end points:* Reduction of grade 2-4 key side effects in the experimental…
The goals of our study are: 1) to evaluate the performance of a single hs-troponin measurement using universal and sex-specific cut-off values; 2) to evaluate whether embedding hs-troponin in a clinical risk score (HEART, INTERCHEST, Marburg Heart…